Immune checkpoint inhibitors (ICIs) have revolutionized urothelial carcinoma (UC) treatment, and are recently shifting upstream in the treatment landscape to localized stages. However, ICIs have to overcome the long-standing dominance of intravesical BCG. While BCG remains the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), it fails in 30–40% of patients according to historical series (1). Combining systemic ICIs…
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)
Annals of Oncology | | Roberto Contieri, Veronica Mollica, Shahrokh F. Shariat, Benjamin Pradere
Topics: bladder-cancer, cervical-cancer, immunotherapy, clinical-trials